SWOG clinical trial number
SWOG-8594

A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer

Closed
Phase
Published
Abbreviated Title
A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer
Activated
10/01/1984
Closed
05/15/1989

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1997

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study.

SB Saxman;KJ Propert;LH Einhorn;ED Crawford;I Tannock;D Raghavan;PJ Loehrer Sr;D Trump Journal of Clinical Oncology 15(7):2564-2569

1992

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study.

PJ Loehrer, Sr;LH Einhorn;PJ Elson;ED Crawford;P Kuebler;I Tannock;D Raghaven;R Stuart-Harris;MF Sarosdy;BA Lowe;B Blumenstein;D Trump JCO 10(17):1066-1073

1990

Advanced bladder cancer: A prospective intergroup trial comparing single agent cisplatin (CDDP) vs. M-VAC combination therapy (INT-0078).

PJ Loehrer;P Elson;JP Kuebler;ED Crawford;I Tannock;D Raghavan;R Stuart-Harris;D Trump;LH Einhorn ASCO 9:132(#511)

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
20%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase